General Information of the Drug (ID: M6APDG03687)
Name
ISIS 114531
Status
Investigative
TTD Drug ID
D08WJY
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
ZNF217 messenger RNA (ZNF217 mRNA)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
Response Summary ZNF217 messenger RNA (ZNF217 mRNA) is a therapeutic target for ISIS 114531. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of ISIS 114531 through regulating the expression of ZNF217 messenger RNA (ZNF217 mRNA). [1], [2]
References
Ref 1 Zfp217 mediates m6A mRNA methylation to orchestrate transcriptional and post-transcriptional regulation to promote adipogenic differentiation. Nucleic Acids Res. 2019 Jul 9;47(12):6130-6144. doi: 10.1093/nar/gkz312.
Ref 2 US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression.